22.52
+3.30%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GenFleet Therapeutics (Shanghai)
Its shares trade on HKEX under the ticker 2595.HK. It has been listed since 19 September 2025. In the fiscal year to 31 December 2024, it reported revenue of CN¥104.7m and a net loss of CN¥677.6m. At that date it held total assets of CN¥606.8m and shareholders' equity of −CN¥1.96bn.
GenFleet Therapeutics (Shanghai) Inc is a CN-based company operating in industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-09-19. GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The firm provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The firm is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The firm mainly primarily operates in the domestic and international markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 19 Sept 2025
- Website
- genfleet.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company is headquartered in Shanghai, China.
- It focuses on developing innovative drugs for tumors, autoimmune, and inflammatory diseases.
- It covers a full range of services from target discovery to clinical development.
Weaknesses
- The company's sector and industry are listed as N/A, indicating unclear market positioning.
- The IPO date is set for 2025-09-19, which is in the future, suggesting it is not yet publicly traded.
- The company operates in a highly competitive pharmaceutical sector without specified differentiation.
Opportunities
- The company aims to provide new treatment solutions for tumors, autoimmune, and inflammatory diseases, which are growing markets.
- It has the potential to expand into international markets as it operates in both domestic and international markets.
- The development of new molecular entities and novel molecular modalities could lead to innovative drug approvals.
Threats
- The company's future IPO date may face delays or market conditions affecting its public listing.
- Operating in the pharmaceutical sector involves high regulatory hurdles and lengthy development cycles.
- The lack of specified sector and industry may hinder investor confidence and market analysis.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.